nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical University10.24884/1561-6274-2018-22-2-50-58nefr-351Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESЭКТОПИЧЕСКАЯ КАЛЬЦИФИКАЦИЯ ПРИ ХРОНИЧЕСКОЙ БОЛЕЗНИ ПОЧЕК. ЧАСТЬ 2. МЕТОДЫ ДИАГНОСТИКИ И ЭФФЕКТИВНОСТЬ ТЕРАПИИECTOPIC CALCIFICATION IN CHRONIC KIDNEY DISEASE. PART 2. THE METHODS OF DIAGNOSTICS AND THE EFFECTIVENESS OF THERAPYЕгшатянЛ. В.EgshatyanL. V.

Егшатян Лилит Ваниковна, кандидат медицинских наук,  центр патологии околощитовидных желез; кафедра эндокринологии и диабетологии МГМСУ имени А.И. Евдокимова

127473, Москва, ул. Делегатская 20, стр. 1

Lilit V. Egshatyan, MD, PhD. Department «pathology of the parathyroid glands»; Chair of Endocrinology and Diabetology at MSUMD 

20\1 Delegatskaya ul. Moscow, 127473

lilit.egshatyan@yandex.ruМокрышеваН. Г.MokryshevaN. G.

Мокрышева Наталья Георгиевна, доктор медицинских наук, центр патологии околощитовидных желез

117036, Москва, ул. Дмитрия Ульянова, д. 11

Natalya G. Mokrysheva, MD, PhD, Department «pathology of the parathyroid glands» 

11 Dmitriya Ulyanova ul. Moscow, 117036

nm70@mail.ruФедеральное государственное бюджетное учреждение «Эндокринологический научный центр» Минздрава РФ; Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияFederal State Budgetary Establishment Endocrinology Research Centre, Ministry of Health of Russia; A.I. Evdokimov Moscow State University of Medicine and DentistryRussian FederationФедеральное государственное бюджетное учреждение «Эндокринологический научный центр» Минздрава РФРоссияFederal State Budgetary Establishment Endocrinology Research Centre, Ministry of Health of RussiaRussian Federation2018120220202225058Copyright © Егшатян Л.В., Мокрышева Н.Г., 20202020Егшатян Л.В., Мокрышева Н.Г.Egshatyan L.V., Mokrysheva N.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/351

В первой части нашей статьи мы обсуждали классификацию и патогенез сосудистой кальцификации, также ее роль в увеличении риска сердечно-сосудистых событий и смертности у пациентов с хронической болезнью почек. В настоящей статье представлен современный обзор литературы, обобщающий данные о методах диагностики и эффекта терапии на выраженность эктопической кальцификации при хронической болезни почек.

 

In the first part of our article, we discussed the classification and pathogenesis of vascular calcification in chronic kidney disease and its impact on increased cardiovascular morbidity and mortality. In this review are discussed the imaging methods and effects of supplementation on progression of ectopic calcification in chronic kidney disease. 

вторичный гиперпаратиреозсосудистая кальцификацияэктопическая кальцификацияхроническая болезнь почекдиагностика кальцификацийкоррекцияsecondary hyperparathyroidismvascular calcificationectopic calcificationchronic kidney diseaseReferencesRennenberg RJ, Kessels AG, Schurgers LJ et al. Vascular calcifications as a marker of increased cardiovascular risk: a metaanalysis. Vasc Health Risk Manag 2009; 5(1):185–197Rennenberg RJ, Kessels AG, Schurgers LJ et al. Vascular calcifications as a marker of increased cardiovascular risk: a metaanalysis. Vasc Health Risk Manag 2009; 5(1):185–197Agatston A, Janowitz W, Hildner F et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15(4):827–832Agatston A, Janowitz W, Hildner F et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol 1990; 15(4):827–832Callister TQ, Cooil B, Raya SP et al. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology 1998; 208: 807–814Callister TQ, Cooil B, Raya SP et al. Coronary artery disease: improved reproducibility of calcium scoring with an electron-beam CT volumetric method. Radiology 1998; 208: 807–814Detrano CR, Anderson M, Nelson J et al. Coronary calcium measurements: Effect of CT scanner type and calcium measure on rescan reproducibility – MESA study. Radiology 2005; 236: 477–484Detrano CR, Anderson M, Nelson J et al. Coronary calcium measurements: Effect of CT scanner type and calcium measure on rescan reproducibility – MESA study. Radiology 2005; 236: 477–484Терновой СК, Морозов СП, Насникова ИЮ и др. Мультиспиральная компьютерная томография коронарных артерий: современные возможности и перспективы. Тер арх 2009;81(4): 79–82 [Ternovoi SK, Morozov SP, Nasnikova IYu i dr. Multislice computed tomography of the coronary arteries: current opportunities and perspectives. Ter. Arch 2009;81(4):79–82. Russian]Терновой СК, Морозов СП, Насникова ИЮ и др. Мультиспиральная компьютерная томография коронарных артерий: современные возможности и перспективы. Тер арх 2009;81(4): 79–82 [Ternovoi SK, Morozov SP, Nasnikova IYu i dr. Multislice computed tomography of the coronary arteries: current opportunities and perspectives. Ter. Arch 2009;81(4):79–82. Russian]Scott DS, Arora UK, Farb A et al. Pathologic validation of a new method to quantify coronary calcific deposits in vivo using intravascular ultrasound. Am J Cardiol 2000; 85(1):37–40Scott DS, Arora UK, Farb A et al. Pathologic validation of a new method to quantify coronary calcific deposits in vivo using intravascular ultrasound. Am J Cardiol 2000; 85(1):37–40Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidn Int 2009; 76 (113): 1–130Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidn Int 2009; 76 (113): 1–130Минеральные и костные нарушения при хронической болезни почек. Национальные рекомендации, подготовленные комитетом экспертов Научного общества нефрологов России (НОНР), 2015. Интернет-ресурс: http://nonr.ru/wp-content/uploads/2013/11 [Mineral’nye i kostnye narusheniya pri hronicheskoj bolezni pochek. Nacional’nye rekomendacii, podgotovlennye komitetom ehkspertov Nauchnogo obshchestva nefrologov Rossii (NONR), 2015. Internet-resurs: http://nonr.ru/wp-content/uploads/2013/11].Минеральные и костные нарушения при хронической болезни почек. Национальные рекомендации, подготовленные комитетом экспертов Научного общества нефрологов России (НОНР), 2015. Интернет-ресурс: http://nonr.ru/wp-content/uploads/2013/11 [Mineral’nye i kostnye narusheniya pri hronicheskoj bolezni pochek. Nacional’nye rekomendacii, podgotovlennye komitetom ehkspertov Nauchnogo obshchestva nefrologov Rossii (NONR), 2015. Internet-resurs: http://nonr.ru/wp-content/uploads/2013/11].National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003 (suppl. 3); 42: S1–S202National kidney Foundation. K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease. Am J Kidney Dis 2003 (suppl. 3); 42: S1–S202Шило ЮВ, Денисов АЮ, Гендлин ГЕ и др. Кардиоваскулярные аспекты нарушений фосфорно-кальциевого обмена у больных на программном гемодиализе. Нефрология 2003; 7(1): 368–369 [Shilo YuV, Denisov AYu, Gendlin GE i dr. Kardio-vaskulyarnye aspekty narushenij fosforno-kal’cievogo obmena u bol’nyh na programmnom gemodialize. Nefrologiya. 2003. 7(1): 368–369 Russian]Шило ЮВ, Денисов АЮ, Гендлин ГЕ и др. Кардиоваскулярные аспекты нарушений фосфорно-кальциевого обмена у больных на программном гемодиализе. Нефрология 2003; 7(1): 368–369 [Shilo YuV, Denisov AYu, Gendlin GE i dr. Kardio-vaskulyarnye aspekty narushenij fosforno-kal’cievogo obmena u bol’nyh na programmnom gemodialize. Nefrologiya. 2003. 7(1): 368–369 Russian]Prentice RL, Pettinger MB, Jackson RD et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int 2013; 24(2):567–580. doi: 10.1007/s00198-012-2224-2 12.Prentice RL, Pettinger MB, Jackson RD et al. Health risks and benefits from calcium and vitamin D supplementation: Women’s Health Initiative clinical trial and cohort study. Osteoporos Int 2013; 24(2):567–580. doi: 10.1007/s00198-012-2224-2 12.Cozzolino M, Brancaccio D. Gallieni C, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease Kidney Int 2005; 68: 429–436Cozzolino M, Brancaccio D. Gallieni C, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease Kidney Int 2005; 68: 429–436Cozzolino M, Dusso AS, Liapis H et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J AmSoc Nephrol J Am Soc Nephrol 2002; 13(9):2299–2308Cozzolino M, Dusso AS, Liapis H et al. The effects of sevelamer hydrochloride and calcium carbonate on kidney calcification in uremic rats. J AmSoc Nephrol J Am Soc Nephrol 2002; 13(9):2299–2308Katsumata K, Kusano K, Hirata M et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kid Int 2003; 64:441–450Katsumata K, Kusano K, Hirata M et al. Sevelamer hydrochloride prevents ectopic calcification and renal osteodystrophy in chronic renal failure rats. Kid Int 2003; 64:441–450Collins A, St. Peter W, Dalleska F et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Neph 2000; 54: 334–341Collins A, St. Peter W, Dalleska F et al. Hospitalization risks between Renagel phosphate binder treated and non-Renagel treated patients. Clin Neph 2000; 54: 334–341Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative en-docrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110(2):229–238Li YC, Kong J, Wei M et al. 1,25-Dihydroxyvitamin D(3) is a negative en-docrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110(2):229–238Schleithoff SS, Zittermann A, Tenderich G et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, ran-domized, placebocontrolled trial. Am J Clin Nutr 2006; 83(4):754–759Schleithoff SS, Zittermann A, Tenderich G et al. Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, ran-domized, placebocontrolled trial. Am J Clin Nutr 2006; 83(4):754–759Verhave G, Siegert C. Role of vitamin D in cardiovascular disease. Neth J Med 2010; 68(3):113–118Verhave G, Siegert C. Role of vitamin D in cardiovascular disease. Neth J Med 2010; 68(3):113–118Rajasree S, Umashankar PR, Lal AV et al. 1,25-dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci 2002; 70(15):1777–1788Rajasree S, Umashankar PR, Lal AV et al. 1,25-dihydroxyvitamin D3 receptor is upregulated in aortic smooth muscle cells during hypervitaminosis D. Life Sci 2002; 70(15):1777–1788Kim DH, Sabour S, Sagar UN et al. Prevalence of hypovitaminosis D in cardi-ovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102(11):1540–1544Kim DH, Sabour S, Sagar UN et al. Prevalence of hypovitaminosis D in cardi-ovascular diseases (from the National Health and Nutrition Examination Survey 2001 to 2004). Am J Cardiol 2008; 102(11):1540–1544Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4):503– 511. doi: 10.1161/CIRCULATIONAHA.107.706127Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation 2008; 117(4):503– 511. doi: 10.1161/CIRCULATIONAHA.107.706127Dobnig H, Pilz S, Scharnag H et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168(12):1340–1349. doi: 10.1001/archinteDobnig H, Pilz S, Scharnag H et al. Independent association of low serum 25-hydroxyvitamin d and 1,25-dihydroxyvitamin d levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168(12):1340–1349. doi: 10.1001/archinteAmer M, Qayyum R. Relationship between 25-Hydroxyvitamin D and All-cause and Cardiovas-cular Disease Mortality. Am J Med 2013; 126(6):509–514. doi: 10.1016/j.amjmed.2012.11.021Amer M, Qayyum R. Relationship between 25-Hydroxyvitamin D and All-cause and Cardiovas-cular Disease Mortality. Am J Med 2013; 126(6):509–514. doi: 10.1016/j.amjmed.2012.11.021Al Mheid I, Patel R, Murrow J et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011; 58(2):186–192. doi: 10.1016/j.jacc.2011.02.051Al Mheid I, Patel R, Murrow J et al. Vitamin D status is associated with arterial stiffness and vascular dysfunction in healthy humans. J Am Coll Cardiol 2011; 58(2):186–192. doi: 10.1016/j.jacc.2011.02.051London GM, Guérin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18(2):613–620London GM, Guérin AP, Verbeke FH et al. Mineral metabolism and arterial functions in end-stage renal disease: potential role of 25-hydroxyvitamin D deficiency. J Am Soc Nephrol 2007; 18(2):613–620Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121(12):193–198. doi: 10.1016/j.jsbmb.2010.03.064.Dusso A, Arcidiacono MV, Yang J, Tokumoto M. Vitamin D inhibition of TACE and prevention of renal osteodystrophy and cardiovascular mortality. J Steroid Biochem Mol Biol 2010; 121(12):193–198. doi: 10.1016/j.jsbmb.2010.03.064.Mathew S, Lund R, Chaudhary L et al. Vitamin D Receptor Activators Can Protect against Vascular Calcification. J Am Soc Nephrol 2008; 19(8):1509–1519. doi: 10.1681/ASN.2007080902Mathew S, Lund R, Chaudhary L et al. Vitamin D Receptor Activators Can Protect against Vascular Calcification. J Am Soc Nephrol 2008; 19(8):1509–1519. doi: 10.1681/ASN.2007080902Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25 dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139(5):279–284Brown AJ, Finch J, Slatopolsky E. Differential effects of 19-nor-1,25 dihydroxyvitamin D2 and 1,25-dihydroxyvitamin D3 on intestinal calcium and phosphate transport. J Lab Clin Med 2002;139(5):279–284Li YC1, Kong J, Wei M et al. 1,25–Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229–238Li YC1, Kong J, Wei M et al. 1,25–Dihydroxyvitamin D(3) is a negative endocrine regulator of the renin-angiotensin system. J Clin Invest 2002; 110:229–238Cardus A, Gallego C, Muray S et al. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia 2003; 23(2):117–121Cardus A, Gallego C, Muray S et al. Differential effect of vitamin D analogues on the proliferation of vascular smooth muscle cells. Nefrologia 2003; 23(2):117–121Hirata M, Katsumata K, Endo K et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transpl 2003;18:1770–1776Hirata M, Katsumata K, Endo K et al. In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3. Nephrol Dial Transpl 2003;18:1770–1776Schroeder NJ, Cunningham J. What’s new in vitamin D for the nephrologist? Nephrol Dial Transplant 2000; 15: 460–466Schroeder NJ, Cunningham J. What’s new in vitamin D for the nephrologist? Nephrol Dial Transplant 2000; 15: 460–466Torun D, Yildiz I, Micozkadioglu H et al. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi J Kidney Dis Transpl 2016; 27(1):15–22. doi: 10.4103/1319-2442.174053Torun D, Yildiz I, Micozkadioglu H et al. The effects of cinacalcet treatment on bone mineral metabolism, anemia parameters, left ventricular mass index and parathyroid gland volume in hemodialysis patients with severe secondary hyperparathyroidism. Saudi J Kidney Dis Transpl 2016; 27(1):15–22. doi: 10.4103/1319-2442.174053Yousaf F, Charytan C. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Ren Fail 2014; 36(1):131–138. doi: 10.3109/0886022X.2013.832319Yousaf F, Charytan C. Review of cinacalcet hydrochloride in the management of secondary hyperparathyroidism. Ren Fail 2014; 36(1):131–138. doi: 10.3109/0886022X.2013.832319Bover J, Perez R, Molina M et al. Renal Osteodystrophy Group of Spanish Society of Nephrology and all investigators from REHISET study. Cinacalcet Treatment for Secondary Hyperparathyroidism in Dialysis Patients: An Observational Study in Routine Clinical Practice. Nephron Clin Pract 2011;118: 109–121. DOI: 10.1159/000319882Bover J, Perez R, Molina M et al. Renal Osteodystrophy Group of Spanish Society of Nephrology and all investigators from REHISET study. Cinacalcet Treatment for Secondary Hyperparathyroidism in Dialysis Patients: An Observational Study in Routine Clinical Practice. Nephron Clin Pract 2011;118: 109–121. DOI: 10.1159/000319882Ohanian J, Gatfield K, Ward D, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 2005; 288: 1756–1762Ohanian J, Gatfield K, Ward D, Ohanian V. Evidence for a functional calcium-sensing receptor that modulates myogenic tone in rat subcutaneous small arteries. Am J Physiol Heart Circ Physiol 2005; 288: 1756–1762Jensen B, Farach-Carson MC, Kenaley E, Akanbi KA. High extracellular calcium attenuates adipogenesis in 3T3–L1 preadipocytes. Exp Cell Res 2004; 301: 280–292Jensen B, Farach-Carson MC, Kenaley E, Akanbi KA. High extracellular calcium attenuates adipogenesis in 3T3–L1 preadipocytes. Exp Cell Res 2004; 301: 280–292Odenwald TRE, Roesch F, Schaefer F, Schmitt CP. The calcimimetic R568 lowers blood pressure, but not total body sodium content, in rats [Abstract]. J Am Soc Neph 2004; 15: 279Odenwald TRE, Roesch F, Schaefer F, Schmitt CP. The calcimimetic R568 lowers blood pressure, but not total body sodium content, in rats [Abstract]. J Am Soc Neph 2004; 15: 279Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–1800Cunningham J, Danese M, Olson K et al. Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int 2005; 68: 1793–1800Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78(6): 578–589. doi: 10.1038/ki.2010.167Block GA, Zaun D, Smits G et al. Cinacalcet hydrochloride treatment significantly improves all-cause and cardiovascular survival in a large cohort of hemodialysis patients. Kidney Int 2010; 78(6): 578–589. doi: 10.1038/ki.2010.167Raggi P, Chertow GM, Torres PU et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus lowdose vitamin D on vascular calcification in patients on hemodialysis. Neph Dial Transp 2010; 1 of 13 doi: 10.1093/ndt/gfq725Raggi P, Chertow GM, Torres PU et al. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus lowdose vitamin D on vascular calcification in patients on hemodialysis. Neph Dial Transp 2010; 1 of 13 doi: 10.1093/ndt/gfq725Yu Z, Gu L, Pang H et al. Sodium thiosulfate: an emerging treatment for calciphylaxis in dialysis patients. Case Rep Neph Dial 2015; 5:77–82 doi: 10.1159/000380945Yu Z, Gu L, Pang H et al. Sodium thiosulfate: an emerging treatment for calciphylaxis in dialysis patients. Case Rep Neph Dial 2015; 5:77–82 doi: 10.1159/000380945Seibel MJ, Robins SP, Bilezikian JP. Editorial: Serum undercarboxylated osteocalcin and the risk of hip fracture. J Clin Endocrinol Metab 1997; 82 (3):717–718Seibel MJ, Robins SP, Bilezikian JP. Editorial: Serum undercarboxylated osteocalcin and the risk of hip fracture. J Clin Endocrinol Metab 1997; 82 (3):717–718Liu C, Wan J, Yang Q et al. Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats. J Huazhong Univ Sci Technolog Med Sci 2008; 28(5):535–538Liu C, Wan J, Yang Q et al. Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats. J Huazhong Univ Sci Technolog Med Sci 2008; 28(5):535–538Rajamannan N, Subramaniam M, Stock S et al. Atorvastatin inhibits calcification and enhances nitric oxide syn-thase production in the hypercholesterolaemic aortic valve. Heart 2005; 91(6):806–810Rajamannan N, Subramaniam M, Stock S et al. Atorvastatin inhibits calcification and enhances nitric oxide syn-thase production in the hypercholesterolaemic aortic valve. Heart 2005; 91(6):806–810Kizu A, Shioi A, Jono S et al. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem 2004; 93(5):1011–1019Kizu A, Shioi A, Jono S et al. Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediators. J Cell Biochem 2004; 93(5):1011–1019Wu B, Elmariah S, Kaplan FS et al. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005; 25(3):592–597Wu B, Elmariah S, Kaplan FS et al. Paradoxical effects of statins on aortic valve myofibroblasts and osteoblasts: implications for end-stage valvular heart disease. Arterioscler Thromb Vasc Biol 2005; 25(3):592–597Mundy G1, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286(5446): 1946–1949Mundy G1, Garrett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999; 286(5446): 1946–1949Gilmanov D, Bevilacqua S, Mazzone A, Glauber M. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg 2010; 11(3):297–301Gilmanov D, Bevilacqua S, Mazzone A, Glauber M. Do statins slow the process of calcification of aortic tissue valves? Interact Cardiovasc Thorac Surg 2010; 11(3):297–301Houslay ES, Cowell SJ, Prescott RJ et al. Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled tri-al. Heart 2006; 92(9):1207–1212Houslay ES, Cowell SJ, Prescott RJ et al. Scottish Aortic Stenosis and Lipid Lowering Therapy, Impact on Regression trial Investigators. Progressive coronary calcification despite intensive lipid-lowering treatment: a randomised controlled tri-al. Heart 2006; 92(9):1207–1212Fisher JE, Rogers MJ, Halasy JM et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96(1): 133–138Fisher JE, Rogers MJ, Halasy JM et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci USA 1999; 96(1): 133–138Kawahara T, Nishikawa M, Kawahara C et al. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation 2013; 127(23):2327–2335. doi: 10.1161/Circulationaha.113.001534Kawahara T, Nishikawa M, Kawahara C et al. Atorvastatin, etidronate, or both in patients at high risk for atherosclerotic aortic plaques: a randomized, controlled trial. Circulation 2013; 127(23):2327–2335. doi: 10.1161/Circulationaha.113.001534Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus 2005; 14(9):773–779Bevilacqua M, Dominguez LJ, Rosini S, Barbagallo M. Bisphosphonates and atherosclerosis: why? Lupus 2005; 14(9):773–779Review. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21(5):817–824Review. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol 2001; 21(5):817–824Tanko LB, Qin G, Alexandersen P et al. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2005; 16(2):184–190Tanko LB, Qin G, Alexandersen P et al. Effective doses of ibandronate do not influence the 3-year progression of aortic calcification in elderly osteoporotic women. Osteoporos Int 2005; 16(2):184–190Toussaint ND, Lau KK, Strauss BJ et al. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 56(1):57–68. doi: 10.1053/j.ajkd.2009.12.039Toussaint ND, Lau KK, Strauss BJ et al. Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis 2010; 56(1):57–68. doi: 10.1053/j.ajkd.2009.12.039Ariyoshi T, Eishi K, Sakamoto I et al. Effect of etidronic acid on arterial calci-fication in dialysis patients. Clin Drug Investig 2006; 26(4):215–222Ariyoshi T, Eishi K, Sakamoto I et al. Effect of etidronic acid on arterial calci-fication in dialysis patients. Clin Drug Investig 2006; 26(4):215–222Addy Montes de Oca, Fatima Guerrero, Julio MartinezMoreno et al. Magnesium Inhibits Wnt/β-Catenin Activity and Reverses the Osteogenic Transformation of Vascular Smooth Muscle Cells. PLoS ONE 2014; 9(2): doi.org/10.1371/journal.pone.0089525Addy Montes de Oca, Fatima Guerrero, Julio MartinezMoreno et al. Magnesium Inhibits Wnt/β-Catenin Activity and Reverses the Osteogenic Transformation of Vascular Smooth Muscle Cells. PLoS ONE 2014; 9(2): doi.org/10.1371/journal.pone.0089525Zelt JG, McCabe KM, Svajger B et al. Magnesium Modifies the Impact of Calcitriol Treatment on Vascular Calcification in Experimental Chronic Kidney Disease. J Pharmacol Exp Ther 2015; 355(3):451–462. doi: 10.1124/jpet.115.228106Zelt JG, McCabe KM, Svajger B et al. Magnesium Modifies the Impact of Calcitriol Treatment on Vascular Calcification in Experimental Chronic Kidney Disease. J Pharmacol Exp Ther 2015; 355(3):451–462. doi: 10.1124/jpet.115.228106Shao JS, Cheng SL, Charlton–Kachigian N et al. Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor– deficient mice. J Biol Chem 2003; 278:50195–50202.Shao JS, Cheng SL, Charlton–Kachigian N et al. Teriparatide (human parathyroid hormone (1–34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor– deficient mice. J Biol Chem 2003; 278:50195–50202.

The authors declare that there are no conflicts of interest present.